MS4A4E Inhibitors
MS4A4E inhibitors include a range of compounds that target specific signaling pathways with which MS4A4E may be associated. Wortmannin and LY294002 are potent PI3K inhibitors that can lead to decreased activity of the PI3K/AKT pathway. This inhibition would decrease AKT phosphorylation, which is crucial for the activation of downstream proteins, potentially reducing MS4A4E activity if it is regulated by or dependent on AKT signaling for its function. Rapamycin, by binding to mTORC1, disrupts mTOR signaling, anotherpathway that could impact MS4A4E's activity if there is a regulatory relationship between mTOR signaling and MS4A4E. Inhibitors such as U0126 and PD98059 target the MEK/ERK pathway, where their action reduces ERK-mediated phosphorylation events. If MS4A4E is a downstream effector of this pathway, then MEK inhibition would result in diminished MS4A4E activity.
Compounds such as SB203580 and SP600125 specifically inhibit p38 MAPK and JNK pathways, respectively. Inhibition of these pathways can lead to decreased activity of proteins regulated by them, including potentially MS4A4E if it is a downstream target. Dasatinib and PP2, as Src family kinase inhibitors, can suppress signaling pathways including PI3K/AKT, thereby affecting MS4A4E activity if it is associated with Src kinase signaling pathways. BAY 11-7082, an NF-κB inhibitor, would impede proteins regulated by NF-κB, and LY3214996 and AZD8055 directly inhibit ERK1/2 and mTORC1/mTORC2, respectively. This direct inhibition could result in decreased activation of downstream targets of these kinases, including MS4A4E, assuming a connection between these kinases and MS4A4E function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which can lead to the inhibition of the PI3K/AKT pathway, resulting in decreased phosphorylation of AKT. If MS4A4E is downstream of PI3K/AKT signaling, its activity could be reduced due to diminished AKT-mediated signaling and phosphorylation events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor and by blocking PI3K, it can suppress the downstream AKT signaling. This suppression can subsequently inhibit the functional activity of MS4A4E, assuming that MS4A4E is regulated by or is a part of this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin targets the mTOR pathway by binding to mTORC1, leading to the inhibition of mTORC1-mediated signaling. Should MS4A4E be influenced by mTOR signaling, the functional activity of MS4A4E would be inhibited as a result of mTORC1 signaling disruption. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2 which are upstream of ERK1/2 in the MAPK pathway. If MS4A4E is activated by the MEK/ERK pathway, then inhibiting MEK would lead to a reduction in ERK-mediated events and thus inhibit MS4A4E activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, it can decrease the functional activity of proteins regulated by p38 MAPK signaling. This would inhibit MS4A4E if its activity is associated with p38 MAPK pathway activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits the JNK pathway, which can lead to a reduction in the functional activity of proteins that are regulated by JNK signaling. If MS4A4E is one such protein, its activity would be inhibited as a consequence of JNK inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad inhibitor of Src family kinases and can suppress various downstream signaling pathways, including those involving PI3K/AKT. If MS4A4E operates downstream of Src family kinases, its activity would be inhibited through the suppression of these kinases. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases and can inhibit the functional activity of proteins regulated by Src kinase signaling. If MS4A4E is regulated by Src kinases, its activity would be reduced due to inhibited Src signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that impedes the activation of the MEK/ERK pathway. If MS4A4E is activated by this pathway, the inhibition of MEK would result in reduced functional activity of MS4A4E due to decreased ERK phosphorylation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an NF-κB inhibitor. By preventing NF-κB activation, this compound can inhibit the functional activity of proteins regulated by NF-κB signaling. If MS4A4E is regulated by NF-κB, its activity would be inhibited as a result of NF-κB pathway inhibition. | ||||||